生脉注射液对乳腺癌术后化疗患者免疫功能的影响  

Effect of Shengmai Injection on Immune Function of Breast Cancer Patients Receiving Chemotherapy After Operation

作　　者：王志兵[1] 嵇冰[1] 陈建华[1] 顾凤元[1] 

机构地区：[1]湖州市中医院普外科,浙江湖州313000

出　　处：《新中医》2015年第3期203-205,共3页New Chinese Medicine

基　　金：浙江省中药医院制剂研究计划(2009YB033)

摘　　要：目的:探讨生脉注射液对乳腺癌术后西他赛+阿霉素+环磷氮芥方案(TAC)化疗患者免疫功能的影响。方法:将60例乳腺癌患者随机分为对照组和观察组各30例。另选取30例乳腺良性疾病术后患者作为正常对照组。对照组给予单纯TAC化疗,观察组在TAC化疗治疗基础上给予生脉注射液静脉滴注。结果:总缓解率观察组为56.67%,对照组为23.33%,2组比较,差异有统计学意义(P<0.01)。化疗前,2组患者IgM、IgG、IgA、CD4+、CD4+/CD8+水平均低于正常对照组(P<0.05,P<0.01)。化疗后,观察组患者IgM、IgG、IgA、CD4+、CD4+/CD8+水平均高于对照组(P<0.05,P<0.01)。治疗后,观察组患者IgM、IgG、IgA、CD4+、CD4+/CD8+水平较化疗前有所上升(P<0.05,P<0.01)。对照组化疗前后免疫功能指标比较,差异无统计学意义(P>0.05)。观察组患者血小板下降、胃肠道反应及白细胞下降的发生率较对照组低。结论:生脉注射液能够有效改善乳腺癌术后化疗患者的免疫功能,减轻毒副反应,提高临床疗效。Objective： To investigate the effect of Shengmai injection on immune function of breast cancer patients receiving tamoxifen, adriamycin, and cyclophosphamide（TAC） chemotherapy after the operation. Methods： Sixty cases of breast cancer patients were randomly divided into TAC group and combination group, 30 patients in each group. Thirty cases of benign breast disease patients after operation were selected as normal control. TAC group were treated with TAC chemotherapy, and the combination group received Shengmai injection combined with TAC chemotherapy. Results： The overall remission rate was 56.67% in the combination group, and was higher than that of 23.33% in TAC group, the difference being significant（P 〈 0.01）. Before chemotherapy, the levels of immunoglobulin M（IgM）, IgG, IgA, CD4＋, CD4＋/CD8＋ in the two medication groups were lower than those in the normal control group（P〈 0.01）. After chemotherapy, the levels of IgM, IgG, IgA, CD4＋, CD4＋/CD8＋ in the combination group were increased（P 〈 0.05 compared with those before chemotherapy）, but the differences between the two medication groups were insignificant （P 〉0.05）. The incidence of platelet descent, gastrointestinal tract reaction, and leucopenia in the combination group was Iowther than that of TAC group. Conclusion： Shengmai injection can effectively improve the immune function, reduce side effect, and improve the clinical efficacy of breast cancer patients receiving chemotherapy after the operation.

关 键 词：乳腺癌 手术 TAC化疗 生脉注射液 免疫功能 

分 类 号：R737.9[医药卫生—肿瘤]